bevacizumab-vikg

**Bevacizumab-vikg** is an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab developed by Outlook Therapeutics for intravitreal use in retinal vascular diseases, particularly neovascular age-related macular degeneration. It is designed as a full-length humanized recombinant monoclonal antibody that binds vascular endothelial growth factor A and inhibits VEGF-driven angiogenesis and vascular permeability, thereby reducing retinal edema, leakage, and pathologic neovascularization. In the provided public-source context, bevacizumab-vikg is the specific active substance in Outlook's program **ONS-5010** and brand **Lytenava**, positioned as a purpose-built ophthalmic alternative to repackaged intravenous bevacizumab used off-label for wet AMD and other retinal diseases such as diabetic macular edema and branch retinal vein occlusion.

Brand names

Lytenava

Other names

ophthalmic bevacizumab-vikgONS-5010/LYTENAVA